Top ▲

Blood coagulation components C

Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).

Overview

Click here for help

« Hide

Coagulation as a process is interpreted as a mechanism for reducing excessive blood loss through the generation of a gel-like clot local to the site of injury. The process involves the activation, adhesion (see Integrins), degranulation and aggregation of platelets, as well as proteins circulating in the plasma. The coagulation cascade involves multiple proteins being converted to more active forms from less active precursors (for example, prothrombin [Factor II] is converted to thrombin [Factor IIa]), typically through proteolysis (see Proteases). Listed here are the components of the coagulation cascade targeted by agents in current clinical usage or at an advanced level of development.

Enzymes

Click here for help

coagulation factor II, thrombin / prothrombin C Show summary » More detailed page go icon to follow link

coagulation factor III, tissue factor C Show summary »

coagulation factor V C Show summary » More detailed page go icon to follow link

coagulation factor VIII C Show summary » More detailed page go icon to follow link

coagulation factor X C Show summary » More detailed page go icon to follow link

coagulation factor XI C Show summary » More detailed page go icon to follow link

antithrombin, antithrombin III (serpin family C member 1) C Show summary » More detailed page go icon to follow link

Comments

Click here for help

Show »

Further reading

Click here for help

Show »

References

Click here for help

Show »

NC-IUPHAR subcommittee and family contributors

Show »

How to cite this family page

Database page citation (select format):

Concise Guide to PHARMACOLOGY citation:

Alexander SPH, Fabbro D, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Davies JA et al. (2023) The Concise Guide to PHARMACOLOGY 2023/24: Enzymes. Br J Pharmacol. 180 Suppl 2:S289-373.